EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
EZH2 is overexpressed in poor-prognostic chronic lymphocytic leukaemia (CLL) cases, acting as an oncogene; however, thus far, the EZH2 target genes in CLL have not been disclosed. In this study, using ChIP-sequencing, we identified EZH2 and H3K27me3 target genes in two prognostic subgroups of CLL wi...
Main Authors: | Subazini Thankaswamy Kosalai, Mohammad Hamdy Abdelrazak Morsy, Nikos Papakonstantinou, Larry Mansouri, Niki Stavroyianni, Chandrasekhar Kanduri, Kostas Stamatopoulos, Richard Rosenquist, Meena Kanduri |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-11-01
|
Series: | Epigenetics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/15592294.2019.1633867 |
Similar Items
-
Insulin receptor substrate 1 overexpression promotes survival of glioblastoma cells through AKT1 activation
by: Gokhan Gorgisen, et al.
Published: (2020-03-01) -
Glucose-Restricted Diet Regulates the Tumor Immune Microenvironment and Prevents Tumor Growth in Lung Adenocarcinoma
by: Alexander Gähler, et al.
Published: (2022-04-01) -
EZH2-Myc Hallmark in Oncovirus/Cytomegalovirus Infections and Cytomegalovirus’ Resemblance to Oncoviruses
by: Ranim El Baba, et al.
Published: (2024-03-01) -
IGF1R activation and the in vitro antiproliferative efficacy of IGF1R inhibitor are inversely correlated with IGFBP5 expression in bladder cancer
by: Yann Neuzillet, et al.
Published: (2017-09-01) -
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
by: Bohan Wang, et al.
Published: (2023-06-01)